Phase II study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A

Sylvia Adams, Peter Schmid, Hope S. Rugo, Eric P. Winer, Delphine Loirat, Ahmad Awada, David W. Cescon, Hiroji Iwata, Mario Campone, Rita Nanda, Rina Hui, Giuseppe Curigliano, Deborah Toppmeyer, Joyce O‘Shaughnessy, Sherene Loi, Shani Paluch-Shimon, Deborah Card, Jing Zhao, Vassiliki Karantza, Javier Cortes

Perlmutter Cancer Center, New York University School of Medicine, New York, NY
Barts Health NHS Trust, London, United Kingdom
University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
Dana-Farber Cancer Institute, Boston, MA
Institut Curie, Paris, France
Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium
Princess Margaret Cancer Centre, Toronto, ON, Canada
Aichi Cancer Center Hospital, Nagoya, Japan
Institut de Cancérologie de l‘Ouest - René Gauducheau, Saint-Herblain, France
The University of Chicago, Chicago, IL
Westmead Hospital, Westmead, Australia
Instituto Europeo di Oncologia, Milano, Italy
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
Baylor University Medical Center, Dallas, TX
Peter MacCallum Cancer Centre, Melbourne, Australia
Sheba Medical Center, Tel HaShomer, Ramat Gan, Israel
Merck & Co., Inc., Kenilworth, NJ
Vall d’Hebron University Hospital Institute of Oncology (VHIO) and Ramon y Cajal University Hospital, Madrid, Spain